FRANKFURT (dpa-AFX Broker) – After a buy recommendation from Societe Generale, the shares of FMC (Fresenius Medical Care (FMC) St) made it above their 50-day line on Friday. At 37.07 euros, they climbed to a high since the price collapse in mid-October. At that time they had collapsed as a result of Novo Nordisk’s research success with its anti-diabetic drug Ozempic. The drug, which primarily makes headlines for its use for weight loss, is considered a danger to dialysis providers because it could slow down the number of kidney patients in the long term.
However, SocGen expert Justin Smith currently sees a “mispricing” in FMC’s shares and advises investors to take advantage of this misjudgment in the market. The topics of obesity and dialysis are unobjectively lumped together, even though they are extremely different. There have already been other, cheaper approaches that have not thrown FMC off track, says Smith. At 71 euros, his price target is at the level of summer 2021./ag/mis
———————-
dpa-AFX Broker – the trader news from dpa-AFX
———————-
Selected leverage products on Fresenius Medical Care (FMC) St.
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products at Fresenius Medical Care (FMC) St.
The leverage must be between 2 and 20
Advertising